Abstract
The chemotherapeutic era of tuberculosis began with the discovery of streptomycin (SM) in 1944 and its trial in 1945 (1,2). Soon after the introduction of isoniazid (INH) in 1952 (3), drug therapy was adopted as an important weapon in the treatment of this ancient disease. In the early stages of chemotherapy, it became apparent that drug resistance and treatment failure resulted when monotherapy with SM was used to treat active disease harboring large bacillary populations (4). The addition of a second drug to the regimen, such as para-amino-salicylic acid (PAS) or INH, prevented the emergence of drug resistance and treatment failure (5,6). Soon, the efficacy of chemotherapy was firmly established. Provided that the appropriate drug combinations were utilized against susceptible pretreatment organisms, tuberculosis could be cured within 18–24 months.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Waksman SA, Bugie E, Schatz A (1944) Isolation of antibiotic substance from soil microorganisms with special reference to streptothricin and streptomycin. Mayo Clin Proc 19:537–548.
Schatz A, Waksman SA (1944) Effect of streptomycin and other substances upon mycobacterium tuberculosis and related organisms. Proc Soc Br Med 57:244–248.
Steenken W Jr, Wolinsky E (1952) Antituberculous properties of hydrazines of isonicotinic acid (Rimifon, Marzilid). Am Rev Tuberc 65:365–375.
British Medical Research Council (1948) Streptomycin treatment of pulmonary tuberculosis: a Medical Research Council investigation. Br Med J 2:769–782.
British Medical Research Council (1950) Treatment of pulmonary tuberculosis with streptomycin and para-amino-salicylic acid: a Medical Research Council investigation. Br Med J 2:1073–1085.
British Medical Research Council (1952) Treatment of pulmonary tuberculosis with isoniazid: an interim report to Medical Research Council by their Tuberculosis Chemotherapy Trials Committee. Br Med J 2:735–746.
Mitchison DA (1965) Chemotherapy of tuberculosis: a bacteriologist’s viewpoint. Br Med J 1:1333–1340.
American Thoracic Society/Centers for Disease Control (1986) Treatment of tuberculosis and tuberculosis infection in adults and children. Am Rev Respir Dis 134:355–363.
Cowie RL, Langton ME, Escreet BC (1985) Ultrashort course chemotherapy for culture-negative pulmonary tuberculosis: a qualified success. S African Med J 68:879–880.
Grosset J (1980) Bacteriologic basis of short course chemotherapy for tuberculosis. Clin Chest Med 1:231–241.
Fox W (1968) The John Barnwell Lecture: changing concepts in the chemotherapy of pulmonary tuberculosis. Am Rev Respir Dis 97:767–790.
Canneti G(1965) The J. Burn’s Amberson Lecture: present aspects of bacterial resistance in tuberculosis. Am Rev Respir Dis 92:687–703.
David HL (1980) Drug resistance to M. tuberculosis and other mycobacteria. Clin Chest Med 11:227–230.
Mitchison DA, Dickinson JM (1978) Bactericidal mechanisms in short course chemotherapy of tuberculosis. Bull Int Union Against Tuberc 53:270–274.
Grosset J (1978) The sterilizing value of rifampicin and pyrazinamide in experimental short course chemotherapy. Tubercle 59:287–297.
Fox W (1981) Whither short course chemotherapy? Br J Dis Chest 75:331–357.
Mackaness GB, Smith N (1953) The bactericidal action of isoniazid, streptomycin and terramycin in extracellular and intracellular tubercle bacilli. Am Rev Respir Dis 67:322–340.
Dickinson JM, Aber VR, Mitchison DA (1977) Bactericidal activity of streptomycin, isoniazid, rifampin, ethambutol and pyrazinamide alone and in combination against Mycobacterium tuberculosis. Am Rev Respir Dis 116:627–635.
Clini V, Grassi C (1970) The action of new antituberculosis drugs on intracellular tubercle bacilli. Antibiot Chemother 16:20–26.
Dickinson JM, Mitchison DA (1981) Experimental models to explain the high sterilizing activity of rifampin in the chemotherapy of tuberculosis. Am Rev Respir Dis 123:367–371.
Mackaness GB (1950) The intracellular activation of pyrazinamide and nicotinamide. Am Rev Tuberc 74:718–721.
Dutt AK, Stead WW (1982) Medical perspective: present chemotherapy for tuberculosis. J Infect Dis 146:698–704.
Fox W (1979) The current status of short course chemotherapy. Tubercle 60:177–190.
Snider DE Jr, Cauthen GM, Farer LS, Kelly GD, Kilburn JO, Grood RC, Dooley SW (1991) Drug resistant tuberculosis (letter). Am Rev Respir Dis 144:732.
Carpenter JL, Obnibene Ai, Gorby EW, Neimes RE, Koch JR, Perkins WL (1983) Antituberculosis drug resistance in South Texas. Am Rev Respir Dis 128:1055–1058.
Chawla PK, Klapper PJ, Kamholz SL, Pollock AH, Heurich AE (1992) Drugresistant tuberculosis in an urban population including patients at risk for human immunodeficiency virus infection. Am Rev Respir Dis 146:280–284.
Frieden TR, Sterling T, Pablos-Mendez A, Kilburn JO, Canthen GH, Dooley SW (1993) The emergence of drug-resistant tuberculosis in New York City. N Engl J Med 328:521–526.
Costello HD, Caras GJ, Snider DE Jr (1980) Drug resistance among previously treated tuberculosis patients: a brief report. Am Rev Respir Dis 121:313–316.
Centers for Disease Control and Prevention (1994) Expanded tuberculosis surveillance and morbidity-United States, 1993. Morbid Mortal Wkly Rep 43 : 361–366.
Ben-Dov I, Mason GR (1987) Drug-resistant tuberculosis in a Southern California hospital: trends from 1969 to 1984. Am Rev Respir Dis 135:1307–1310.
Barnes PF (1987) The influence of epidemiologic factors on drug resistance rates in tuberculosis. Am Rev Respir Dis 136:325–328.
Riley LW, Arathoon E, Loverde VD (1989) The epidemiologic patterns of drugresistant Mycobacterium tuberculosis: a community-based study. Am Rev Respir Dis 139:1282–1285.
Cantwell MF, Snider DE Jr, Cauthen GM, Onovato IM (1994) Epidemiology of tuberculosis in the United States, 1985 through 1992. J Am Med Assoc 272:532–539.
Snider DE Jr, Kelly GD, Cauthen GM, Thompson NJ, Kilburn JO (1985) Infection and disease among contacts of tuberculosis cases with drug-resistant and drugsusceptible bacilli. Am Rev Respir Dis 132:125–132.
Steiner M, Zimmerman R, Park BH, Shinali SR, Schmidt H (1968) Primary tuberculosis in children: correlation of susceptibility patterns from M. tuberculosis isolated from children with those isolated from source case as an index of drug resistant infection in a community. Am Rev Respir Dis 8:201–209.
Nardell E, McInnis B, Thomas B, Weidhass S (1986) Exogenous reinfection with tuberculosis in a shelter for the homeless. N Engl J Med 315:1570–1575.
Iseman MD (1993) Treatment of multidrug-resistant tuberculosis. N Engl J Med 329:784–791.
Stead WW, Dutt AK (1982) Chemotherapy for tuberculosis today. Am Rev Respir Dis 125:94–101.
Mitchison DA, Nunn AJ (1986) Influence of initial drug resistance in the response to short course chemotherapy of pulmonary tuberculosis. Am Rev Respir Dis 133:423–430.
Mitchison DA (1992) Understanding the chemotherapy of tuberculosis: current problem. J Antimicrob Chemother 29:477–493.
Dutt AK, Stead WW (1980) Chemotherapy of tuberculosis for the 1980s. Clin Chest Med 1:243–252.
British Thoracic and Tuberculosis Association (1976) Short-course chemotherapy in pulmonary tuberculosis: a controlled trial. Lancet 2:1102–1104.
Dutt AK, Jones L, Stead WW (1979) Short-course chemotherapy for tuberculosis with largely twice-weekly isoniazid-rifampin. Chest 75 :441 – 447.
Dutt AK, Moers D, Stead WW (1984) Short course chemotherapy for tuberculosis with mainly twice weekly isoniazid and rifampin: community physician’s seven years experience with mainly outpatients. Am J Med 77:233–242.
Dutt AK, Moers D, Stead WW (1980) Results of short course chemotherapy for tuberculosis in patients with complicating medical disorders. Chest 78:514 (abstract).
Dutt AK, Moers D. Stead WW (1986) Short course chemotherapy for extrapulmonary tuberculosis. Ann Intern Med 104:7–12.
Abernathy RS, Dutt AK, Stead WW, Moers DJ (1983) Short course chemotherapy for tuberculosis in children. Pediatrics 12:801–806.
Snider DE Jr, Zierski M, Graczyk J, et al. (1986) Short-course tuberculosis chemotherapy studies conducted in Poland during the past decade. Eur J Respir Dis 68:12–18.
Manalo F, Tan F, Sbarbaro JA, Iseman MD (1990) Community-based short-course treatment of pulmonary tuberculosis in a developing nation. Am Rev Respir Dis 142:1301–1305.
Steele MA, Des Prez RM (1988) The role of pyrazinamide in tuberculosis chemotherapy. Chest 94:845–850.
Girling DJ (1989) The chemotherapy of tuberculosis. Biol Mycobact 3:285–294.
Centers for Disease Control (1993) Initial therapy for tuberculosis in the era of multidrug resistance: recommendations of the Advisory Council for the Elimination of Tuberculosis. Morbid Mortal Wkly Rep 42(RR-7):1–8.
Goble M (1986) Drug resistant tuberculosis. Semin Respir Infect 1:220–229.
Iseman MD, Madsen LA (1989) Drug-resistant tuberculosis. Clin Chest Med 10:341–353.
Goble M, Iseman MD, Madsen LA, Waite D, Ackerson L, Horsburgh CRIV, (1993) Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. N Engl J Med 328:527–532.
Imamura N, Vanderkolk J, Heifets L (1994) Inhibitory and bactericidal activities of levofloxacin against Mycobacterium tuberculosis in vitro and in human macrophages. Antimicrob. Agents Chemotherap. 38(5):1161–1164.
Iseman MD, Madsen L, Goble M, Pomerantz M (1990) Surgical intervention in the treatment of pulmonary disease caused by drug-resistant Mycobacterium tuberculosis. Am Rev Respir Dis 141:623–625.
Stead WW, To T, Harrison RW, Abraham JH III (1987) Benefit-risk considerations in preventive treatment for tuberculosis in elderly persons. Ann Intern Med 107:843–845.
International Union Against Tuberculosis Committee on Prophylaxis (1982) Efficacy of various duration of isoniazid preventive therapy for tuberculosis: five year followup in the IVAT trial. Bull WHO 60:555–564.
Koplan JP, Farer LS (1980) Choice of preventive treatment for isoniazid-resistant tuberculosis infection. J Am Med Assoc 244:2736–2740.
Centers for Disease Control (1992) Management of persons exposed to multidrugresistant tuberculosis. Morbid Mortal Wkly Rep 41(RR-11):61–74.
Centers for Disease Control. The role of BCG vaccine in the prevention and control of tuberculosis in the United States: a joint statement by the advisory council for the elimination of tuberculosis. MMWR 1996;45(RR-4):1–18.
Small PM, Schecter GF, Goodman PC, Sande MA, Chaisson RE, Hopewell PC (1992) Treatment of tuberculosis in patients with advanced human immunodeficiency virus infection. N Engl J Med 324:289–294.
Jones BE, Otaya M, Antoniskis D, Sian S, Wang F, Mercado A, Davidson PT, Barnes PF (1994) A prospective evaluation of antituberculosis therapy in patients with human immunodeficiency virus infection. Am J Respir Crit Care Med 150:1499— 1502.
Centers for Disease Control (1991) Nosocomial transmission of multidrug-resistant tuberculosis among HIV-infected persons: Florida and New York 1988–1991. Morbid Mortal Wkly Rep 40(34):585–591.
Edlin BR, Tokars JI, Grieco MH, Crawford JT, William J, Sordillo EM, Ong KR, Kilburn J, Dooley SW, Castro KG, Jarvis WR, Holmberg SD (1992) An outbreak of multidrug-resistant tuberculosis among hospitalized patients with the acquired immunodeficiency syndrome. N Engl J Med 326:1514–1521.
Alwood K, Kevuly J, Moore-Rice K, Stanton DL, Chaulk CD, Chaisson RE (1994) Effectiveness of supervised intermittent therapy for tuberculosis in HIV infection. AIDS 8:1103–1108.
Fischl MA, Daikos GL, Uttamchandani RD, Poblete RB, Moreno JN, Reyes RR, Boota AM, Thompson LM, Cleary TJ, Oldham SA (1992) Clinical presentation and outcome of patients with HIV infection and tuberculosis caused by multiple drug resistant bacilli. Ann Intern Med 117:184–190.
A comparative study of daily and twice-weekly continuation regimens of tuberculosis chemotherapy, including a comparison of two durations of sanatorium treatment. I. First report: the results at 12 months. Bull World Health Organ 1971:45(5):573–593.
Starke JR (1990) Multidrug therapy for tuberculosis in children. Pediatr Infect Dis J 9:785–793.
Committee on Infectious Diseases (1991) Report of the Committee on Infectious Diseases, 22nd Ed., Elk Grove, IL: American Academy of Pediatrics.
Anonymous: Smear negative pulmonary tuberculosis. Tubercle 1980;61:113–115.
Narain R, Nair SS, Naganna K (1968) Problem of defining a case of pulmonary tuberculosis in prevalence survey. Bull WHO 39:701–729.
Dutt AK, Stead WW (1994) Smear-negative pulmonary tuberculosis. Semin Respir Infect 9(2):113–119.
Singapore Tuberculosis Service/British Medical Research Council (1986) Long-term follow-up of a clinical trial of six-month and four-month regimens of chemotherapy in the treatment of pulmonary tuberculosis. Am Rev Respir Dis 133:779–783.
Hong Kong Chest Service/Tuberculosis Research Center Madras/British Medical Research Council (1989) A controlled trial of 3-month, 4-month and 6-month regimens of chemotherapy for sputum smear-negative pulmonary tuberculosis: results at 5 years. Am Rev Respir Dis 139:871–876.
American Thoracic Society/Centers for Disease Control (1994) Recommendations for the treatment and preventive treatment of tuberculosis. Am J Respir Crit Car Med 151:1359–1374.
Dutt AK, Moers D, Stead WW (1990) Smear-negative culture-positive pulmonary tuberculosis: six months chemotherapy with isoniazid and rifampin. Am Rev Respir Dis 144:1232–1235.
Dutt AK, Moers D, Stead WW (1992) Tuberculous pleural effusion: six month therapy with isoniazid and rifampin. Am Rev Respir Dis 145:1429–1432.
Ormerod LP, McCarthy OR, Rudd RM, Horsfield N, (1995) Short course chemotherapy for tuberculous pleural effusion and culture-negative pulmonary tuberculosis. Tuber Lung Dis 76:25–27.
Dutt AK, Moers D, Stead WW (1989) Smear- and culture-negative pulmonary tuberculosis: four months short course chemotherapy. Am Rev Respir Dis 139:867–870.
Snider DE Jr, Layde RN, Johnson MW, Lyle MA (1980) Treatment of tuberculosis during pregnancy. Am Rev Respir Dis 122:65–79.
Snider DE Jr, Powell KE (1984) Should women taking antituberculosis drugs breast feed? Arch Intern Med 144:589–590.
Hamadeh MA, Glassroth J (1992) Tuberculosis and pregnancy. Chest 101:1114–1120.
Cross FS, Long MW, Banner AS, Snider DE, Jr (1980) Rifampin-isoniazid therapy of alcoholic and non-alcoholic tuberculosis patients in a U.S. Public Health Service Cooperative Therapy trial. Am Rev Respir Dis 122:349–353.
Andrew OT, Schoenfeld PY, Hopewell PC, Humphrey’s MH (1980) Tuberculosis in patients with end-stage renal disease. Am J Med 68:59–65.
Dautzenberg B, Grosset J, Fechner J, Luccianni, Debra P, Hersons S, Truffot C, Sors C (1984) The management of thirty immunocompromised patients with tuberculosis. Am Rev Respir Dis 129:494–496.
Davidson PT, Le HQ: Drug treatment of tuberculosis-1992. Drugs 43:651–673.
Masud T, Kemp E (1988) Corticosteroids in treatment of disseminated tuberculosis in patients with HIV infection. Br Med J 296:464–465.
Strang JIG, Kakaza MMS, Gibson DG, Allen BW, Mitchison DA, Evans DJ, Girling DJ, Nunn AJ, Fox, W (1988) Controlled clinical trial of complete open surgical drainage and of prednisolone in treatment of tuberculous pericardial effusion in Transkei. Lancet 2:759–764.
Brudney K, Dobkin J (1991) Resurgent tuberculosis in New York City: human immunodeficiency virus, homelessness and the decline of tuberculosis program. Am Rev Respir Dis 144:745–749.
Mahmoudi A, Iseman MD (1993) Pitfalls in the care of patients with tuberculosis: common errors and their association with the acquisition of drug resistance. J Am Med Assoc 270:65–68.
Brudney K, Dobkin J (1991) A tale of two cities: tuberculosis in Nicaragua and New York City. Semin Respir Infect 6:261–272.
Weis SE, Slocum PC, Blais FX, King B, Matney GB, Gomez E, Foresman BH (1994) The effect of directly observed therapy on the rate of drug resistance and relapse in tuberculosis. N Engl J Med 330:1179–1184.
Cohn DL, Catlin BJ, Peterson KL, Judson FN, Sbarbaro JA, (1990) A 62-dose, sixmonth therapy for pulmonary and extrapulmonary tuberculosis: a twice weekly, directly observed and cost-effective regimen. Ann Intern Med 112:407–415.
Iseman MD, Cohn DL, Sbarbaro JA (1993) Directly observed treatment of tuberculosis: we can’t afford not to try it. N Engl J Med 328:576–578.
Moulding T, Dutt AK, Reichman LB (1998) Fixed dose combinations of antituberculosis medications to prevent drug resistance. Ann Intern Med 122:951— 954.
Van-den-Brande P, Van-Steenbergen W, Vervoort G, Demedts M (1995) Aging and hepatotoxicity of isoniazid and rifampin in pulmonary tuberculosis Am J Respir Crit Care Med 152, 1705–1708.
Byrd RB, Horn BR, Soloman DA, Griggs GA, (1979) Toxic effects of isoniazid in tuberculosis chemoprophylaxis: role of biochemical monitoring in 1000 patients. J Am Med Assoc 241:1239–1241.
Bailey WC, Taylor SC, Dascomb WH, Greenberg HB, Ziskind MM (1973) Disturbed hepatic function during isoniazid chemoprophylaxis. Am Rev Respir Dis 107:523— 529.
Dutt AK, Moers D, Stead WW (1983) Undesirable side effects of isoniazid and rifampin in largely twice-weekly short-course chemotherapy for tuberculosis. Am Rev Respir Dis 128:419–424.
Girling DJ (1978) The hepatic toxicity of antituberculosis regimens containing isoniazid, rifampicin and pyrazinamide. Tubercle 59:13–32.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1998 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Dutt, A.K., Mehta, J.B. (1998). Chemotherapy of Tuberculosis in Developed Countries. In: Gangadharam, P.R.J., Jenkins, P.A. (eds) Mycobacteria. Chapman & Hall Medical Microbiology Series. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-7511-5_5
Download citation
DOI: https://doi.org/10.1007/978-1-4615-7511-5_5
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4615-7513-9
Online ISBN: 978-1-4615-7511-5
eBook Packages: Springer Book Archive